FDA Approves First Biosimilar to Neulasta to Help Reduce the Risk of Infection During Cancer Treatment

The U.S. Food and Drug Administration today approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

July Newsletter 2018

The Colorado Center for Gynecologic Oncology is excited to share our July Newsletter providing patients with new information, upcoming events and inspiring stories. This month’s Feature Article, “44 Ways to Make the Day of Someone with Cancer” was written by Dr. Elana Miller, physician and cancer survivor. Based on her personal experience, she has compiled…